Latest Conference Articles

An analysis of 7 trials examining cardiovascular outcomes of study drugs found that concomitant insulin use increased a patient’s risk of severe cardiovascular outcomes.

A meta-analysis of 3 real-world studies into the effectiveness of Abbot's FreeStyle Libre Flash Glucose Monitoring System at ADA 2019.

A recent study from ADA 2019 found that rates of depression, mental illness, and antidepressant use among diabetes patients have increased significantly from 2010 to 2016.

Investigators from Allegheny Health Network examined the impact of a multidisciplinary team approach on glycemic control in patients with diabetes in a primary care setting.

An analysis of results from the EXSCEL trial has suggested that exenatide with SGLT2 inhibitors may reduce major cardiovascular events and improve renal health.

A new study from ADA showed the investigative monoclonal antibody suppressed development and diagnosis of T1D in at-risk patients.

A new retrospective cohort analysis found that patients with type 2 diabetes generally have about 12 months following BI initiation to achieve A1c < 7.0%.

Type 2 diabetes patient outcomes including heart failure, stroke, and myocardial infarction were weighed between the 2 popular drug classes.

A study of the massive 2005 trial data found that fenofibrate-targeted biomarkers are closely associated to cardiovascular risks in patients with T2D.

A decision for icosapent ethyl's sNDA is not expected to come from the FDA until September, but excitement surrounding the drug is at all-time high.

UNC professor of medicine discusses her thoughts on the largest challenges for physicians to overcome in the future of diabetes treatment.

Early initiation of GLP-1RA and SGLT2 in patients with T2D resulted in higher odds for long term HbA1C control and for lower CV risk factors.

The longest clinical assessment of a GLP-1 receptor agonist for cardiovascular outcomes showed a 12% decrease in MACE versus placebo.

An age-stratified analysis of Swedish national registry data found that myocardial infarction and heart failure rates may even be more prevalent in patients with T1D.

Sue Kirkman, MD, professor of medicine at UNC Chapel Hill, discusses the results of a study she led that attempted to create a method of identifying what type of diabetes through EHR data.

John Buse, MD, professor of medicine at UNC Chapel Hill, discusses the results and implications of the PIONEER 7 trial.

It's been 5 years since the FDA approved empagliflozin, and 4 since the major outcomes findings. What is its role in diabetes care today?

The three-year trial reported that initial weight loss plus 1 of any 4 diet and exercise programs is associated with major benefits for at-risk patients.

A review of REDUCE-IT data prior to an FDA supplemental new drug application decision shows the unprecedented benefit of the fish oil therapy.

Todd Hobbs, MD, chief medical officer of Novo Nordisk North America, discusses the results of PIONEER 4 at ADA 2019 in San Francisco, CA.

Todd Hobbs, MD, chief medical officer at Novo Nordisk North America, discusses what prompted Novo Nordisk to create oral semaglutide.

Todd Hobbs, MD, CMO of Novo Nordisk, discusses the findings of the PIONEER 2 study.

New findings show the controversial 2018 blood sugar control recommendations are associated with cost benefits for 3 subgroups of affected T2D patients.

A new study which considered the suggested association between type 2 diabetes and vitamin D deficiency did not show a statistically significant reduction of patient risk.

Ruben Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses treating myelofibrosis with ruxolitinib therapy.

Ruben Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses the visible symptoms and diagnosis process for patients with myelofibrosis.

New trial results show the cytotoxin delivers clinical responses in patients with untreated or relapsed forms of the rare disease.

The common, concerning adverse effect requires a careful eye from clinicians and new therapy options.